Assessing human papillomavirus vaccine efficacy and safety.
Clinical trials have documented the safety, efficacy, and immunogenicity of the quadrivalent and bivalent human papillomavirus (HPV) L1 virus-like particle vaccines. These vaccines have demonstrated greater than 90% efficacy in preventing HPV-related neoplasias of the lower genital tract. The quadrivalent HPV vaccine has been found to be more than 95% efficacious in preventing genital warts. These vaccines have been shown to protect against a wider range of oncogenic HPV types. Nonetheless, women must continue to have routine cervical cytologic screening. This article reviews the clinical trials document the efficacy of the HPV vaccines.
Hendrix
Susan L
SL
4727 St Antoine, Suite 304, Detroit, MI 48201-1461, USA. SHendrix@dmc.org
D005260:Female; D052162:Human papillomavirus 16; D052161:Human papillomavirus 18; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000009:adverse effects*
D053918:Papillomavirus Vaccines